No products in the cart.

Anti-HLA-DR antibody

SKU Product Brand Unit Availability Price Quantity  
AB-06-2211
Anti-HLA-DR antibody
Erpan Tech In stock

Specifications        

Product Cat#: AB-06-2211
Product type: Primary antibody
Antigen: HLA-DR
Immunogen: Peptide
Species immunized: Mouse (10-D8)
Isotype: IgG1
Applications: Western Blot (1:600-1:000); Immunohistochemistry (1:60-1:200); Flow Cytometry (1:60-1:200)
Reactivity: Human
Clonality (clone number): Monoclonal (10-D8)
Form: Liquid
Buffer: Tris-HCl buffer (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide.
Concentration: 2 mg/ml
Purity: Peptide affinity purified
Storage: Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles.
Alternative names: DR alpha chain antibody
DR alpha chain precursor antibody
DRA_HUMAN antibody
DRB1 antibody
DRB4 antibody
Histocompatibility antigen HLA DR alpha antibody
HLA class II histocompatibility antigen antibody
HLA class II histocompatibility antigen DR alpha chain antibody
HLA DR1B antibody
HLA DR3B antibody
HLA DRA antibody
HLA DRA1 antibody
HLA DRB1 antibody
HLA DRB3 antibody
HLA DRB4 antibody
HLA DRB5 antibody
HLA-DRA antibody
HLADR4B antibody
HLADRA1 antibody
HLADRB antibody
Major histocompatibility complex class II DR alpha antibody
Major histocompatibility complex class II DR beta 1 antibody
Major histocompatibility complex class II DR beta 3 antibody
Major histocompatibility complex class II DR beta 4 antibody
Major histocompatibility complex class II DR beta 5 antibody
MGC117330 antibody
MHC cell surface glycoprotein antibody
MHC class II antigen DRA antibody
MHC II antibody
MLRW antibody
Show More

Target information

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Provider

Erpantech Laboratory

download

MSDS-AB-06-2211.pdf (151 downloads )